Johnson & Johnson ​reported a slightly higher-than-expected profit on Tuesday driven by strong sales of immune disease treatment Tremfya, and said it plans ‌to spin off its hips and knees business next year.

Log in or sign up to comment.

No comments yet.

← Back to stories